Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β super family. It has multiple effects on development, physiology and diseases. However, the role of GDF11 in the development of mesenchymal stem cells (MSCs) is not clear. To explore the effects of GDF11 on the differentiation and pro-angiogenic activities of MSCs, mouse bone marrow-derived MSCs were engineered to overexpress GDF11 (MSC ) and their capacity for differentiation and paracrine actions were examined both in vitro and in vivo. Expression of endothelial markers CD31 and VEGFR2 at the levels of both mRNA and protein was significantly higher in MSC than control MSCs (MSC ) during differentiation. More tube formation was observed in MSC as compared with controls. In an in vivo angiogenesis assay with Matrigel plug, MSC showed more differentiation into CD31 endothelial-like cells and better pro-angiogenic activity as compared with MSC . Mechanistically, the enhanced differentiation by GDF11 involved activation of extracellular-signal-related kinase (ERK) and eukaryotic translation initiation factor 4E (EIF4E). Inhibition of either TGF-β receptor or ERK diminished the effect of GDF11 on MSC differentiation. In summary, our study unveils the function of GDF11 in the pro-angiogenic activities of MSCs by enhancing endothelial differentiation via the TGFβ-R/ERK/EIF4E pathway.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412688 | PMC |
| http://dx.doi.org/10.1111/jcmm.15502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.
Blood Adv
September 2025
Zhongnan Hospital of Wuhan University, Wuhan, China.
The role of inflammation in the regulation of acute myeloid leukemia (AML) and stressed hematopoiesis is significant, though the molecular mechanisms are not fully understood. Here, we found that mesenchymal stromal cells (MSCs) had dysregulated expression of the inflammatory cytokine S100A8 in AML. Upregulating S100A8 in MSCs increased the proliferation of AML cells in vitro.
View Article and Find Full Text PDFIdentification of critical process parameters and quality attributes for bioreactor-based expansion of human MSCs.
Front Bioeng Biotechnol
August 2025
Department Bio-Adaptive production, Fraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Mesenchymal stem/stromal cells (MSCs) have been identified as a promising therapeutic option for osteoarthritis, graft vs. host disease and cardiovascular diseases, among others. For widespread application of these therapies, robust and scaled manufacturing processes are required that reliably yield high amounts of high quality MSCs.
View Article and Find Full Text PDFMHC compatibility influences the interaction between different types of equine mesenchymal stem/stromal cells and the local immune response.
Res Vet Sci
September 2025
Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS) - Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza-CITA, Zaragoza, Spain; Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, Zaragoza, Spain. El
The allogeneic administration of equine mesenchymal stem/stromal cells (MSCs) has numerous advantages over autologous therapy, but their interactions with the patient's immune system need to be further elucidated. These interactions can be influenced by factors such as the compatibility between donor-receptor for the major histocompatibility complex (MHC) and by the MHC expression levels, which can change under different conditions like inflammatory exposure and chondrogeneic differentiation. In this study, we evaluated the local immune response induced by chondrogeneically differentiated (MSC-chondro), pro-inflammatory primed (MSC-primed) and basal (MSC-naïve) MSCs, and how this response changes the immunomodulatory and immunogenic profiles of MSCs in vivo.
View Article and Find Full Text PDFMesenchymal stromal cells 2.0: thinking outside the box.
Front Immunol
September 2025
Department of Pharmacology and Physiology, Université de Montréal, Montreal, QC, Canada.
Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells that can be derived from a variety of sources including bone marrow and adipose tissues among others. MSCs are plastic adherent and easy to culture , making them attractive platforms for cell-based technologies. They have an impressive immunoplasticity and can express a suppressive or inflammatory phenotype depending on their stimuli.
View Article and Find Full Text PDFDeep learning predicts osteogenic differentiation stages of human mesenchymal stem cells from phase-contrast microscopy images.
Dent Mater J
September 2025
Department of Medical Systems Engineering, Graduate School of Biomedical and Health Sciences, Hiroshima University.
In this study, we constructed and validated deep learning models capable of predicting the osteogenic differentiation stages of mesenchymal stem cells (MSCs) using only phase-contrast microscopy images. UE7T-13, an immortalized human MSC line, was cultured in osteoinductive medium. Phase-contrast microscopy images were acquired at D0, D1, D5, D10, and D14 of differentiation.
View Article and Find Full Text PDF